Abstract
AML1-ETO fusion protein is observed in approximately 12% of acute myeloid leukemia. In the present research, we found that AML1-ETO is able to inhibit Sp1 transactivity. We also found that this inhibition of Sp1 transactivity by AML1-ETO is achieved by interaction between Sp1 and RUNT domain of AML1. AML1b is able to abrogate the inhibition of AML1-ETO. Since Sp1 is involved in hematopoietic cell differentiation, we proposed that AML1-ETO promotes leukemogenesis by blocking cell differentiation through inhibition of Sp1 transactivity.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Cell Line
-
Core Binding Factor Alpha 2 Subunit / metabolism*
-
Hematopoietic Stem Cells / cytology
-
Hematopoietic Stem Cells / metabolism
-
Humans
-
Leukopoiesis / genetics*
-
Oncogene Proteins, Fusion / metabolism*
-
Protein Structure, Tertiary
-
RUNX1 Translocation Partner 1 Protein
-
Sp1 Transcription Factor / antagonists & inhibitors*
-
Sp1 Transcription Factor / metabolism
-
Transcriptional Activation*
Substances
-
AML1-ETO fusion protein, human
-
Core Binding Factor Alpha 2 Subunit
-
Oncogene Proteins, Fusion
-
RUNX1 Translocation Partner 1 Protein
-
RUNX1 protein, human
-
Sp1 Transcription Factor